findmyKOL
Clinical trialNCT02702817CompletedPhase 2Interventional

Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia

SponsorDouglas Mental Health University InstituteEnrollment200Alzheimer DiseaseCognitive Decline Due to Alzheimer DiseaseMild Cognitive Impairment Due to Alzheimer Disease
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • John C S Breitner, MD, MPH

    Dept of Psychiatry, McGill University Faculty of Medicine

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Douglas Hospital Research Centre

    Montreal, Quebec, Canada

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Aug 2012
Primary completion
31 Mar 2017
Completion
15 Jul 2017
Last update posted
1 Aug 2017
Registered enrollment
200
Registry id
NCT02702817

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.